Analyst Report: CRL
1. EXECUTIVE SUMMARY
Charles River Laboratories rose 19.08% over the week to a close of $357.27 on 26 October, a new 52-week high, after two large sessions on 20 October (+5.14%) and 21 October (+9.33%). The sources disagree on the cause of the 21 October move. StocksToTrade and Timothy Sykes tie it to the "Pathway to Purpose" investor day and a run of target raises, while AlphaStreet attributes it to a sector-wide rally with no company news. No source explains the 20 October or 26 October sessions. The stock now trades above every analyst target in the brief, including UBS's $357, with third-quarter results due on 4 November.
2. THE CATALYST
The brief offers two explanations for the 21 October jump, and they conflict.
- Analyst and strategy narrative. StocksToTrade and Timothy Sykes (21 October) reported that RBC, BofA, UBS, Jefferies, Deutsche Bank, Baird and Morgan Stanley raised price targets and kept bullish ratings after an upbeat analyst day. Management's plan targets 5–7% organic revenue growth from 2027 to 2030, margin expansion toward 24%, low double-digit EPS gains and more than $300M of cost savings. The same coverage said 2026 EPS guidance was reaffirmed at the high end of the $11.15–$11.45 range, against a $11.33 Street view.
- Sector narrative. AlphaStreet (21 October) said the gain came from a broad sector rally, citing similar percentage gains at Illumina and Medpace, and found no Charles River-specific development.
The dating of the analyst actions weakens the first account. Defense World and MarketScreener place the sourced raises earlier: RBC and Baird on 25 September, Jefferies on 28 September, UBS on 30 September, Morgan Stanley on 12 October and JPMorgan on 14 October. Those all predate the 20–21 October rally. The investor day date is also unconfirmed, since one listing places a 1.87% fall after an investor day on 7 October.
| Session | Close | Change | Volume | Sourced driver |
|---|---|---|---|---|
| 20 Oct | $315.45 | +5.14% | 1,273,500 | None found |
| 21 Oct | $344.87 | +9.33% | 2,744,500 | Disputed: investor day and targets, or sector rally |
| 22 Oct | $339.66 | -1.51% | 2,662,200 | Minor collaboration news, no linked move |
| 23 Oct | $345.37 | +1.68% | 822,300 | None found |
| 26 Oct | $357.27 | +3.45% | 1,175,900 | None found |
3. COMPANY PROFILE
Charles River provides drug discovery, non-clinical development and safety testing services, and its Research Models and Services segment supplies purpose-bred rodents and related research services. It sits in the Healthcare sector, in Diagnostics & Research, with a market cap of $17.06bn and a forward P/E of 28.0. Peers in life sciences tools and services include Thermo Fisher, Danaher, Illumina, Waters, Agilent and IQVIA.
Per ad-hoc-news (20 October), second-quarter 2026 revenue was $1.00 billion, down 2.70% from $1.03 billion a year earlier. GAAP operating margin rose to 11.90% from 9.70%. The company posted a GAAP loss of $0.03 per diluted share, which ad-hoc-news linked to a $63.70 million loss tied to divestitures. StocksToTrade also listed the Pathoquest acquisition, which adds next-generation sequencing and non-animal biologics testing, and the Apollo Orchestrate QC platform.
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? The brief supports a rerating on the guidance and the multi-year plan, if StocksToTrade's account is accurate. Revenue fell 2.70% in the second quarter, though, so the shares now price in a recovery that the reported numbers have not yet shown. The move from $300.02 to $357.27 took the stock above the MarketBeat average target of $302.33 and the MarketScreener figure of $314.20, as reported by Defense World and MarketScreener.
Peer read-across. Over the same period peers rose: TMO +0.81%, DHR +3.81%, ILMN +3.19%, WAT +5.00%, A +3.57% and IQV +2.90%. Every peer gained less than Charles River's 19.08%, and the S&P 500 fell 0.18%. This indicates the sector lifted the shares but company-specific buying accounts for most of the move (inference).
Comparable episodes. On 5 August the stock rose about 11% on Q2 earnings, institutional demand and target raises, while CLSA downgraded to Hold (Timothy Sykes). A headline from the Usearch listing reports a 7.23% rise on 24 September, which I could not verify against the underlying article. The shares are up 76.50% year to date and 53.66% over 60 sessions, so repeated target raises have accompanied a long run.
Bull case. Guidance sits at the high end of the range, the cost-savings programme exceeds $300M, and the 2027–2030 targets give analysts room to lift estimates. Volume of 1,175,900 on the latest session was 1.17x the 50-session average, and the stock closed at its high of the week.
Bear case. The shares trade above nearly all published targets, the cause of the largest single-day gain is disputed, and a director's share sales were reported by Investing.com (27 October) and Stock Titan (22 October), read as headlines only. An officer's proposed sale of 2,156 shares was filed for 21 October (Stock Titan Form 144).
5. TECHNICAL SNAPSHOT
The close of $357.27 is the highest in the daily table and sits at the 52-week high of $357.77, so no resistance level is available from the data. It stands well above the 50-day average of $295.49 and the 200-day average of $218.82, and 144.4% above the 52-week low of $146.20 from 19 May. The nearest support is the 23 October close of $345.37, followed by $344.87 from 21 October. Volume peaked at 2,744,500 and 2,662,200 on 21 and 22 October, about 2.7 times the 50-session average, and has since settled near the average.
6. RISK FACTORS
- Earnings on 4 November. The consensus estimate is EPS of $2.97 on revenue of $960.36m. A result that falls short of this after a 19% rally would test the support levels above.
- Unexplained gains. Three of the five sessions in the week have no sourced driver, so the buying may lack durable backing.
- Valuation and targets. At a forward P/E of 28.0 the stock sits above consensus targets, which leaves room for analysts to lift estimates or the shares to drift lower.
- Insider selling. Director and officer sales were reported during the rally.
- Sector reversal. AlphaStreet's explanation implies that a fade in sector sentiment would reach Charles River as well.
7. ACTIONABLE OUTLOOK
Short term (1–2 weeks): The 4 November report dominates. Guidance language, the revenue trend after the 2.70% second-quarter decline and any update on the cost savings will decide whether the $345 area holds. Analysis only, not personal financial advice.
Medium term (1–3 months): Further target raises toward and above the current price would support the shares. Without them, the gap between the price and the $302.33 to $314.20 consensus targets leaves room for a pullback.
Long term: The thesis rests on the 2027–2030 plan of 5–7% organic growth and margin expansion toward 24%. The brief does not confirm that this plan changed the picture on 21 October, so the long-term view stays tied to delivery against those targets.